cell and gene therapy world


Japan Symposium


PLENARY Session : Wednesday, January 24, 2018
9:00-11:00 AM

Japan has a fully integrated plan to advance and accelerate regenerative medicine products. Key Japanese leaders from academia, industry and government will present at this must-attend for anyone seeking to gain first-hand knowledge and insight into what is happening in Japan.

Chair’s Introduction: Takashi Asada, PhD, Professor, Kyoto University

Symposium Overview: Norio Nakatsuji, Professor Emeritus, Kyoto University and Chief Advisor, Stem Cell & Device Lab., Inc.

Keynote Address from Academia: Hideyuki Okano, MD, PhD Professor, Keio University Medical School; Director of the Japanese Society for Regenerative Medicine (JSRM)

Regulator’s Perspective: Yoji Sato, PhD, Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences (Japan)

Industry Keynote Address: Akihiko Iwai, PhD Vice President, Astellas Pharma, Inc.; Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM)

Masato Ibuki, Regenerative Medicine and Cell Therapy Laboratories, KANEKA Corporation

Masayo Yumoto, PhD, Group Leader, Basic Research Group, Regenerative Medicine Research & Planning Division, Rohto Pharmaceutical, Co., Ltd

Followed by the Japan Partnering Lunch

Japan Partnering Lunch

Recent regulatory evolution, an increasing focus for Japanese big pharma on accessing Western innovation and markets, and the rapid emergence of a robust, specialised tool and service provider sector with global aspirations have all combined to place Japan right at the forefront of cell & gene therapy. Licensing, partnering, outsourcing, development and commercialisation opportunities abound, but collaboration is absolutely critical to the success of each one. Don’t miss Phacilitate and the World Stem Cell Summit’s unique, informal Japan Partnering Lunch, which will be attended by some 50 delegates from Japan spanning the public sector (including regulatory professionals), leading academics and pharma, biotech and CMO decision makers. A select group of Western stakeholders will be invited to attend for free and gain the inside track on success not just in Japan, but across the Asia Pacific region. Register your interest here to be considered for a seat at this rarest and most exclusive of tables.

Regenerative Medicine CMOs in Japan

A recent conversation with long-time Phacilitate collaborators and Japanese sector experts, CJ Partners, highlighted the quite extraordinary recent growth in the Japanese specialist CMO market – but nowhere else could we find a definitive list of the players in this rapidly evolving sector and their capabilities. With manufacturing such a critical and complex component for any cell & gene therapy company seeking to develop and commercialise in Japan, we felt it was high time someone put together a definitive, up-to-the-minute list of the specialist CMO options available across the nation to serve as a reference point for the global sector.

We hope you enjoy this unique infographic!

regenerative medicine cmo japan

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK